Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 2:20 PM
Ignite Modification Date:
2025-12-24 @ 2:20 PM
NCT ID:
NCT00618995
Brief Summary:
The purpose of this study is to evaluate the potential effects of ER niacin/laropiprant, ER niacin, laropiprant, and placebo over the course of seven days on urinary levels of a specific metabolite (which is a marker of in vivo platelet reactivity).
Detailed Description:
Subjects will receive 1 of 4 treatments per period and will eventually receive all 4 treatments:
Treatment A: ER niacin 2g/laropiprant 40 mg daily + Placebo to laropiprant for 7 days
Treatment B: ER niacin 2 g daily + Placebo to laropiprant for 7
days
Treatment C: laropiprant 40 mg daily + Placebo to ER niacin/laropiprant for 7 days
Treatment D: placebo daily for 7 days. There will be at least a 7-day interval between dosing on Day 7 of a period and dosing on Day 1 of the subsequent period
Study:
NCT00618995
Study Brief:
Protocol Section:
NCT00618995